1. Inicio
  2. Publicaciones
  3. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

  • Marcos López Hoyos

    Autor

Autores ajenos al IDIVAL

  • Lozano-Ojalvo, D
  • Camara, C
  • Lopez-Granados, E
  • Nozal, P
  • Del Pino-Molina, L
  • Bravo-Gallego, LY
  • Paz-Artal, E
  • Pion, M
  • Correa-Rocha, R
  • Ortiz, A
  • Iribarren, ME
  • Portoles, J
  • Rojo-Portoles, MP
  • Ojeda, G
  • Cervera, I
  • Gonzalez-Perez, M
  • Bodega-Mayor, I
  • Montes-Casado, M
  • Portoles, P
  • Perez-Olmeda, M
  • Oteo, J
  • Sanchez-Tarjuelo, R
  • Pothula, V
  • Schwarz, M
  • Brahmachary, M
  • Tan, AT
  • Le Bert, N
  • Berin, C
  • Bertoletti, A
  • Guccione, E
  • Ochando, J

Unidades

Abstract

The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
2211-1247, 2211-1247

CELL REPORTS  CELL PRESS

Tipo:
Article
Páginas:
109570-109570
PubMed:
34390647
Enlace a otro recurso:
www.sciencedirect.com

Citas Recibidas en Web of Science: 78

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • COVID-19; T-cell immunity; BNT162b2 vaccine; SARS-CoV-2

Proyectos asociados

Definición de Panel de Inmunidad Protectora frente al COVID

Investigador Principal: Marcos López Hoyos

2020UIC22-PUB-0019 . GOBIERNO DE CANTABRIA . 2020

Compartir